4.5 Article

Hyperspectral imaging for early detection of oxygenation and perfusion changes in irradiated skin

Journal

JOURNAL OF BIOMEDICAL OPTICS
Volume 17, Issue 2, Pages -

Publisher

SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
DOI: 10.1117/1.JBO.17.2.026010

Keywords

hyperspectral imaging; spectroscopy; radiation; radiodermatitis; perfusion; skin

Ask authors/readers for more resources

Studies examining acute oxygenation and perfusion changes in irradiated skin are limited. Hyperspectral imaging (HSI), a method of wide-field, diffuse reflectance spectroscopy, provides noninvasive, quantified measurements of cutaneous oxygenation and perfusion. This study examines whether HSI can assess acute changes in oxygenation and perfusion following irradiation. Skin on both flanks of nude mice (n = 20) was exposed to 50 Gy of beta radiation from a strontium-90 source. Hyperspectral images were obtained before irradiation and on selected days for three weeks. Skin reaction assessment was performed concurrently with HSI. Desquamative injury formed in all irradiated areas. Skin reactions were first seen on day 7, with peak formation on day 14, and resolution beginning by day 21. HSI demonstrated increased tissue oxygenation on day 1 before cutaneous changes were observed (p < 0.001). Further increases over baseline were seen on day 14, but returned to baseline levels by day 21. For perfusion, similar increases were seen on days 1 and 14. Unlike tissue oxygenation, perfusion was decreased below baseline on day 21 (p < 0.002). HSI allows for complete visualization and quantification of tissue oxygenation and perfusion changes in irradiated skin, and may also allow prediction of acute skin reactions based on early changes seen after irradiation. (c) 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.2.026010]

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Stereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates

Jesse Aronowitz, Linda Ding, Jennifer Yates, Yang Zong, Larry Zheng, Zhong Jiang, Jessica Yancey, Kriti Mittal, Thomas J. Fitzgerald

Summary: In this retrospective study of 8 patients, stereotactic body radiotherapy (SBRT) was found to be effective and well-tolerated in controlling gross hematuria caused by urothelial carcinoma of the kidney. Treatment led to cessation of bleeding without significant adverse effects, although it was associated with a moderate decline in renal function.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2021)

Article Oncology

Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group

Lynn Million, Andrea Hayes-Jordan, Yueh-Yun Chi, Sarah S. Donaldson, Suzanne Wolden, Carol Morris, Stephanie Terezakis, Fran Laurie, Karen Morano, T. J. Fitzgerald, Torunn I. Yock, David A. Rodeberg, James R. Anderson, Rose Anne Speights, Jennifer O. Black, Cheryl Coffin, Mary Beth McCarville, Simon C. Kao, Douglas S. Hawkins, Sheri L. Spunt, R. Lor Randall

Summary: The ARST0332 trial for pediatric and young adults with NRSTS utilized risk-based treatment to achieve high local control rates, particularly after R0 resection. Most patients were able to undergo delayed R0/R1 resection after neoadjuvant therapy, leading to improved survival outcomes.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Review Oncology

A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study

John M. Varlotto, Zhuoxin Sun, Bonnie Ky, Jenica Upshaw, Sharyn Katz, Thomas J. Fitzgerald, Heather Wakelee, Maximilian Diehn, David A. Mankoff, Christine Lovely, Chandra Belani, Kurt Oettel, Gregory Masters, Suresh Ramalingam, Nathan A. Pennell

Summary: The ECOG-ACRIN EA5181 trial is investigating the use of concomitant immunotherapy during chemo/radiation for locally advanced non-small cell lung cancer (LA-NSCLC) to reduce local failure risk and improve overall survival. This study is at the forefront of exploring the potential benefits of combining immunotherapy with standard treatment in LA-NSCLC patients.

ONCOLOGIST (2021)

Editorial Material Oncology

Young Adult Populations Face Yet Another Barrier to Care With Insurers: Limited Access to Proton Therapy

Thomas J. FitzGerald

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Article Oncology

Practice Patterns of Pediatric Total Body Irradiation Techniques: A Children's Oncology Group Survey

Prema Rassiah, Natia Esiashvili, Arthur J. Olch, Chia-Ho Hua, Ken Ulin, Andrea Molineu, Karen Marcus, Mahesh Gopalakrishnan, Susha Pillai, Nataliya Kovalchuk, An Liu, Greg Niyazov, Jose Penagaricano, Fred Cheung, Adam C. Olson, Cheng-Chia Wu, Harish K. Malhotra, Iain J. MacEwan, Jacqueline Faught, John C. Breneman, David S. Followill, Thomas J. FitzGerald, John A. Kalapurakal

Summary: The study examined current practice patterns in pediatric total body irradiation (TBI) techniques among COG member institutions. Results showed inconsistencies in practice patterns and a lack of standardization, making it difficult to correlate TBI doses with clinical outcomes effectively.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)

Article Oncology

Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma

Jeff M. Michalski, Anna J. Janss, L. Gilbert Vezina, Kyle S. Smith, Catherine A. Billups, Peter C. Burger, Leanne M. Embry, Patricia L. Cullen, Kristina K. Hardy, Scott L. Pomeroy, Johnnie K. Bass, Stephanie M. Perkins, Thomas E. Merchant, Paul D. Colte, Thomas J. Fitzgerald, Timothy N. Booth, Joel M. Cherlow, Karin M. Muraszko, Jennifer Hadley, Rahul Kumar, Yuanyuan Han, Nancy J. Tarbell, Maryam Fouladi, Ian F. Pollack, Roger J. Packer, Yimei Li, Amar Gajjar, Paul A. Northcott

Summary: In children with average-risk medulloblastoma, reducing the radiation boost volume is safe and does not compromise survival. Decreasing CSI dose in young children leads to inferior outcomes, possibly in a subgroup-dependent manner, but is associated with better neurocognitive outcome. Molecularly informed patient selection may be further explored for late-effect sparing approaches in children with MB.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Review Oncology

A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181

John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, Jenica Upshaw, Thomas J. Fitzgerald, Max Diehn, Christine Lovly, Chandra Belani, Kurt Oettel, Gregory Masters, Matthew Harkenrider, Helen Ross, Suresh Ramalingam, Nathan A. Pennell

Summary: The ECOG-ACRIN EA5181 trial aims to investigate whether adding durvalumab to standard chemo/radiation followed by consolidative durvalumab can improve overall survival and reduce local failure in patients with locally advanced, unresectable non-small cell lung cancer. The trial also explores the synergistic effects of chemotherapy and immunotherapy, radiation therapy history, and the concerns regarding cardiac and pulmonary toxicities.

CLINICAL LUNG CANCER (2022)

Letter Hematology

Extranodal presentation in limited-stage diffuse large B-cell lymphoma as a prognostic marker in three SWOG trials S0014, S0313 and S1001

Deborah M. Stephens, Hongli Li, Louis S. Constine, Thomas J. Fitzgerald, John P. Leonard, Brad S. Kahl, Joo Y. Song, Michael L. LeBlanc, Sonali M. Smith, Daniel O. Persky, Jonathan W. Friedberg

HAEMATOLOGICA (2022)

Review Oncology

Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science

Linda Ding, Carla Bradford, I-Lin Kuo, Yankhua Fan, Kenneth Ulin, Abdulnasser Khalifeh, Suhong Yu, Fenghong Liu, Jonathan Saleeby, Harry Bushe, Koren Smith, Camelia Bianciu, Salvatore LaRosa, Fred Prior, Joel Saltz, Ashish Sharma, Mark Smyczynski, Maryann Bishop-Jodoin, Fran Laurie, Matthew Iandoli, Janaki Moni, M. Giulia Cicchetti, Thomas J. FitzGerald

Summary: The future of radiation oncology is promising due to advances in treatment management platforms, improved treatment execution, and the ability to share and analyze data globally. The use of advanced imaging technology has improved disease targeting, reduced treatment times, and increased treatment convenience. Global data exchange allows for collaboration and validation of findings, promoting further advancements in the field.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Definitive Radiation Therapy for Medically Inoperable Endometrial Carcinoma

James L. Shen, Kevin W. O'Connor, Janaki Moni, Susan Zweizig, Thomas J. Fitzgerald, Eric C. Ko

Summary: This study evaluated the CFS, CSS, and OS of patients with endometrial carcinoma managed with upfront radiation therapy. The results showed that upfront radiation therapy provided excellent CFS, CSS, and OS for patients with endometrial carcinoma. This is important for patients who are unable to undergo surgical intervention.

ADVANCES IN RADIATION ONCOLOGY (2023)

Review Oncology

Quality improvements in radiation oncology clinical trials

Koren Smith, Kenneth Ulin, Michael Knopp, Stephan Kry, Ying Xiao, Mark Rosen, Jeff Michalski, Matthew Iandoli, Fran Laurie, Jean Quigley, Heather Reifler, Juan Santiago, Kathleen Briggs, Shawn Kirby, Kate Schmitter, Fred Prior, Joel Saltz, Ashish Sharma, Maryann Bishop-Jodoin, Janaki Moni, M. Giulia Cicchetti, Thomas J. FitzGerald

Summary: Clinical trials have become the key method for validating improvements in oncology clinical practice. There have been significant advancements in radiation oncology practice, including the use of advanced technology, image guidance, and artificial intelligence in treatment planning. These improvements have enhanced the quality of patient care and expanded the use of radiation therapy in primary disease settings.

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

An Analysis of Major Target Deviations in Craniospinal Irradiation Treatment Plans for Patients With Intermediate-Risk Medulloblastoma Within a Phase 3 Clinical Trial (Children?s Oncology Group Study ACNS0331)

Joshua P. Schiff, Yimei Lee, Yu Wang, Stephanie M. Perkins, Sandy K. Kessel, Thomas J. Fitzgerald, Nicole A. Larrier, Jeff M. Michalski

Summary: Accurate delineation of targets is crucial in craniospinal irradiation treatment, and while technological advances improve conformity, caution is necessary.

ADVANCES IN RADIATION ONCOLOGY (2023)

Editorial Material Oncology

Editorial: Rising stars in radiation oncology 2022

T. J. FitzGerald

FRONTIERS IN ONCOLOGY (2023)

Article Oncology

Children's Oncology Group's 2023 blueprint for research: Radiation oncology

John A. L. Kalapurakal, Suzanne L. Wolden, Daphne N. Haas-Kogan, Nadia N. Laack, Chia-ho C. Hua, Arnold C. E. Paulino, Christine E. S. Hill-Kayser, Bradford S. J. Hoppe, Thomas J. Fitzgerald, COG Radiation Oncology Discipline Com

Summary: Radiation oncology plays a crucial role in the care of children with cancer, aiming to deliver the safest and most effective radiation therapy while minimizing toxicity to normal tissues. The committee provides mentorship to young doctors and actively contributes to the education of the global radiation oncology community. They are leaders in discovering new radiosensitizers, radioprotectors, and advanced radiation therapy technologies to improve outcomes for children with cancer.

PEDIATRIC BLOOD & CANCER (2023)

Article Oncology

Outcomes After Stereotactic Body Radiation Therapy as a Bridging Modality to Liver Transplantation for Hepatocellular Carcinoma

Rashi Garg, Kimberly Foley, Babak Movahedi, Mark J. Masciocchi, Jacob R. Bledsoe, Linda Ding, Paul Rava, Thomas J. Fitzgerald, Shirin Sioshansi

Summary: The study retrospectively analyzed the outcomes of 27 patients receiving SBRT as a bridging treatment while awaiting LT, and found that SBRT was a safe and effective option with a pCR rate of 62%, without causing additional radiation-related complications, and no significant correlation between tumor size and pCR rate.

ADVANCES IN RADIATION ONCOLOGY (2021)

No Data Available